Pharmacological Treatment in Parkinson's Disease
Journal of the Korean Neurological Association
;
: 335-344, 2019.
Article
in Korean
| WPRIM
| ID: wpr-766827
ABSTRACT
Parkinson's disease is one of the most common neurodegenerative disorders world widely. Although curable therapies are practically not available yet, symptomatic managements using anti-Parkinson medications have shown to be quite effective to improve patients' quality of life. The discovery of dopaminergic deficits in Parkinson's disease in 1960s have brought about the human clinical trials of levodopa, which opened an “Era of Dopamine” in treatment history of the Parkinson's disease. Levodopa still remains gold standard. Dopamine agonists have proved their efficacies and delayed the development of long-term complications of levodopa use. Inhibitors of respective enzyme monoamine oxidase-B and catechol-O-methyltransferase, anticholinergics, and amantadine strengthen the therapeutic effects via either monotherapy or adjunctive way. Strategy of continuous dopaminergic stimulation and disease modification are weighing in current advances. This article is providing evidence-based review of pharmacological treatment of Parkinson's disease from early to advanced stages as well as management its unavoidable adverse reactions.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Parkinson Disease
/
Quality of Life
/
Amantadine
/
Levodopa
/
Catechol O-Methyltransferase
/
Dopamine Agonists
/
Cholinergic Antagonists
/
Neurodegenerative Diseases
/
Therapeutic Uses
/
Drug Therapy
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Neurological Association
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS